• About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Clinical Advisory Board
  • Product Candidates
  • Recent News
    • Press Releases
    • Research + Whitepapers
    • News
  • Contact Us

Password Protected

Password Protected

This page is used by password-protected to preview the form on customizer

Recent Posts

  • NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity
  • The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science
  • NIMML Institute to Present Novel Clinical and Translational Data of Omilancor in Ulcerative Colitis Patients at Digestive Disease Week 2025
  • The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical and Translational Science
  • NImmune Biopharma Acquires Development and Commercialization Rights to Omilancor in Asian Markets

Recent Comments

No comments to show.
  • About Us
  • Management Team
  • Board of Directors
  • Clinical Advisory Board
  • Product Candidates
  • Contact Us

Copyright © 2024 NImmune Biopharma